These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 22214393)

  • 41. 2010 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2010 Mar; 6(2):158-94. PubMed ID: 20298981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An economic evaluation of donepezil in the treatment of Alzheimer's disease.
    Small GW; Donohue JA; Brooks RL
    Clin Ther; 1998; 20(4):838-50. PubMed ID: 9737841
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 45. International price comparisons of Alzheimer's drugs: a way to close the affordability gap.
    Suh GH; Wimo A; Gauthier S; O'Connor D; Ikeda M; Homma A; Dominguez J; Yang BM;
    Int Psychogeriatr; 2009 Dec; 21(6):1116-26. PubMed ID: 19735595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
    Wimo A; Winblad B; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Mastey V; Haglund A; Zhang R; Miceli R; Chin W; Subbiah P;
    Dement Geriatr Cogn Disord; 2003; 15(1):44-54. PubMed ID: 12457078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic evaluation of donepezil in moderate to severe Alzheimer disease.
    Feldman H; Gauthier S; Hecker J; Vellas B; Hux M; Xu Y; Schwam EM; Shah S; Mastey V;
    Neurology; 2004 Aug; 63(4):644-50. PubMed ID: 15326236
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States.
    Migliaccio-Walle K; Getsios D; Caro JJ; Ishak KJ; O'Brien JA; Papadopoulos G;
    Clin Ther; 2003 Jun; 25(6):1806-25. PubMed ID: 12860500
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2002; 20(13):919-42. PubMed ID: 12381243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
    Getsios D; Blume S; Ishak KJ; Maclaine GD
    Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
    Barthold D; Joyce G; Ferido P; Drabo EF; Marcum ZA; Gray SL; Zissimopoulos J
    J Alzheimers Dis; 2020; 76(2):579-589. PubMed ID: 32538845
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of Medicare prescription drug coverage on the use of antidementia drugs.
    Fowler NR; Chen YF; Thurton CA; Men A; Rodriguez EG; Donohue JM
    BMC Geriatr; 2013 Apr; 13():37. PubMed ID: 23621892
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New anti-AD drugs--their possibilities and issues].
    Nakamura Y
    Seishin Shinkeigaku Zasshi; 2012; 114(3):255-61. PubMed ID: 22568059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
    Neumann PJ; Hermann RC; Kuntz KM; Araki SS; Duff SB; Leon J; Berenbaum PA; Goldman PA; Williams LW; Weinstein MC
    Neurology; 1999 Apr; 52(6):1138-45. PubMed ID: 10214734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Donepezil. Pharmacoeconomic implications of therapy.
    Foster RH; Plosker GL
    Pharmacoeconomics; 1999 Jul; 16(1):99-114. PubMed ID: 10539126
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008.
    Lazzeroni LC; Halbauer JD; Ashford JW; Noda A; Hernandez B; Azor V; Hozack N; Hasson N; Henderson VW; Yesavage JA; Tinklenberg JR
    J Alzheimers Dis; 2013; 36(4):791-8. PubMed ID: 23703151
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 2011 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2011 Mar; 7(2):208-44. PubMed ID: 21414557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
    Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L
    Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.